Kranus Health GmbH

Kranus Health is building the world's first AI-enabled gender medicine platform — a new category of care for urological and gynecological conditions that affect more than a billion people globally yet remain systematically under-treated. Headquartered in Munich, the company develops clinically validated digital therapy programsranging from urinary incontinence to benign prostatic hyperplasia and overactive bladder, with a pipeline extending into prostate cancer, menopause, breast cancer, and endometriosis. All launched products are permanently reimbursed under Germany's DiGA framework, one of the world's most rigorous digital health standards, and are backed by randomized controlled trials published in NEJM Evidence, The Lancet Digital Health, and European Urology Focus. A regulated, AI-native software factory enables the company to launch new therapeutic indications at unprecedented speed, reshaping the economics of digital medicine.